Antiangiogenic treatment with a humanized monoclonal VEGF-antibody, bevacizumab, has become standard care in primary and recurrent ovarian cancers and several multi-target tyrosine kinase inhibitors of VEGF-pathway have been introduced into the treatment of other types of cancer [6–8]. This evidence concerns the gene VEGFA and ovarian carcinoma.